December, 2008

Re: INTERCEPT Blood System™
Plasma Processing Set (Product Codes INT310X)
Label Claim Expansion & Processing Set Label Modifications

Dear Valued Customer,

CERUS is committed to providing you with quality products and services. This letter is to inform you of changes that are being implemented in our INTERCEPT Blood System product line. We are pleased to advise you of an expansion to our label claims and improvements to the INTERCEPT Plasma processing set labeling.

New Product Claims

The INTERCEPT Blood System for plasma can be used as an alternative to gamma irradiation to prevent transfusion-associated graft-versus-host disease (TA-GVHD) in at-risk patients (subject to local regulations and requirements). Fresh frozen plasma is not routinely irradiated prior to transfusion. However, treatment of plasma with INTERCEPT provides additional measure of safety. This label claim expansion has been approved by our Notified Body, TÜV SÜD Product Service, based on T cell inactivation data, which is used in clinical practice in place of gamma irradiation. The INTERCEPT Blood System for plasma Technical Data Sheet has been updated and a copy can be requested through your local sales representative or Cerus BV Customer Services.

Processing Set Improvements

The following modifications to the processing set labels and Instructions for Use (IFU) have been made.

1. Removal of amotosalen solution expiry dating on the amotosalen solution container label. The expiry dating on the amotosalen container label was removed to avoid set expiry dating confusion. The processing set expiry dating can be found on the aluminum foil pouch label and the shipping carton.

2. The lot logo symbol on the amotosalen container has been removed. The lot logo symbol was removed to avoid customer confusion regarding the lot number of the set. The lot number of the processing set can be found on the aluminum foil pouch, storage container and shipping carton labels.

The pictures below depict the changes to the amotosalen labels:

PREVIOUS plasma set amotosalen label



NEW plasma set amotosalen label



3. Removal of the maximum daily intake limit of 1300µg amotosalen from the "Notes to Physicians" section of the IFU supported by toxicology data, expert opinions, and published literature.

4. Method for air expression between the plasma storage containers have been simplified for ease of use and greater plasma recovery.

Existing inventory of processing sets packaged with the previous IFU and labels will continue to be distributed until such inventory is depleted; however, you may contact Customer Services to request a copy of the new IFU. Upon availability (expected to be within Q3 2008), and after such request, the new IFU will be sent to you.

We trust you will find these improvements useful and are available for any questions or inquiries.

Contact information

If you have any questions concerning this change, please contact Cerus BV Customer Services:

Stationsstraat 79-D
3811 MH Amersfoort
The Netherlands

Email: customer_services@cerus.com
Phone: +31 33 496 0600
Fax: +31 33 496 0606

With Kind Regards,

Cerus Europe BV